Aprea Therapeutics Announces Submission of IND Application

DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage...

Related Keywords

Pennsylvania ,United States ,Mike Moyer ,Oren Gilad ,Nasdaq ,Securities Exchange ,Exchange Commission ,Aprea Therapeutics Inc ,Us Food Drug Administration ,Investigational New Drug ,Drug Administration ,Securities Act ,Securities Exchange Act ,Financial Condition ,Nasdaq Apre ,Aprea Therapeutics ,